SCHEDULE 13D/A: AyurMaya Capital Management Discloses 15.8% Stake in Alumis Inc. Following Merger Completion

AyurMaya Capital Management Company, LP and David E. Goel have disclosed a 15.8% beneficial ownership stake in Alumis Inc. following the completion of a merger where ACELYRIN shares were converted into Alumis common stock.

Summary

• This document is Amendment No. 2 to a Schedule 13D filing, updating previous disclosures regarding beneficial ownership in Alumis Inc.
• The filing reports the completion of a merger on May 21, 2025, where each outstanding share of ACELYRIN common stock was cancelled and converted into 0.4814 shares of Alumis Inc. Common Stock.
• As a result of this merger, the AyurMaya Fund received approximately 4,493,741 shares of Alumis Inc. Common Stock in exchange for its 9,334,735 ACELYRIN Shares.
• AyurMaya Capital Management Company, LP and David E. Goel now beneficially own an aggregate of 15,139,707 shares of Alumis Inc. Common Stock.
• This beneficial ownership represents 15.8% of Alumis Inc.'s common stock, calculated based on approximately 95,819,723 shares outstanding following the effective time of the merger.
• The reporting persons hold shared voting and shared dispositive power over these 15,139,707 shares.

Sentiment

Score: 7

Explanation: The document reports the successful completion of a merger and the resulting ownership stake, indicating a planned corporate action has been executed without any negative surprises or delays mentioned. This suggests a neutral to positive execution of a corporate event.

Positives

• Completion of the merger as planned, leading to the conversion of ACELYRIN shares into Alumis Inc. common stock.
• AyurMaya Capital Management Company, LP and David E. Goel have established a significant beneficial ownership stake of 15.8% in Alumis Inc., indicating a substantial investment.

Risks

• The Reporting Persons will file an amendment to the Schedule 13D if the actual number of shares of Common Stock received differs materially from the approximate number disclosed.

Future Outlook

The reporting persons have stated they will file an amendment to the Schedule 13D if the actual number of shares of Common Stock received differs materially from the approximate number disclosed.

Industry Context

This filing details a significant ownership change in Alumis Inc. resulting from a corporate merger, which is a common strategic activity within the biotechnology and pharmaceutical industries for consolidation or portfolio expansion.

Stakeholder Impact

• Shareholders of ACELYRIN had their shares converted into Alumis Inc. common stock, impacting their holdings and making them shareholders of Alumis Inc.
• Shareholders of Alumis Inc. will see a change in the ownership structure, with AyurMaya Capital Management and David E. Goel becoming significant beneficial owners, potentially influencing future corporate decisions.

Next Steps

• Reporting Persons will file an amendment to the Schedule 13D if the actual number of shares of Common Stock received differs materially from the approximate number disclosed.

Key Dates

Keywords

Alumis Inc., ACELYRIN, Schedule 13D, beneficial ownership, merger, share conversion, institutional ownership, SEC filing, AyurMaya Capital Management, David E. Goel, common stock